奧賽康(002755.SZ):半年度淨利潤預增78.58%-131.50%
格隆匯7月14日丨奧賽康(002755.SZ)公佈2025年半年度業績預告,1-6月公司實現歸屬於上市公司股東的淨利潤盈利1.35億元—1.75億元,比上年同期增長78.58%—131.50%;扣除非經常性損益後的淨利潤盈利1.15億元—1.45億元,比上年同期增長108.58%—162.99%;基本每股收益盈利0.14元/股—0.18元/股。
公司近兩年有多款新上市產品逐步開展商業化銷售,爲公司業務帶來新的增長點,公司營業收入實現同比增長,盈利能力進一步提升。公司爲實現可持續發展,提升核心競爭力,繼續維持高比例研發投入。隨着公司研發管線的不斷推進,部分藥品已進入三期臨牀研發階段,按照會計政策對相關研發投入進行資本化,導致本期研發費用有所下降。公司繼續加強成本管理,優化各類費用開支,減少銷售費用和管理費用的支出,成本費用控制成效顯著。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.